Cyclic nucleotide-gated channel alpha 3

AGTC to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, March 2, 2021
Vision, Branches of biology, Nervous system, Ion channels, Channelopathies, Achromatopsia, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa, Retinitis

Audio webcasts of the presentation at the H.C. Wainwright and ROTH conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations .

Key Points: 
  • Audio webcasts of the presentation at the H.C. Wainwright and ROTH conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations .
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Executives Awarded First Place in the BioProcess International Reader’s Choice Awards, Cell & Gene Therapies Category

Retrieved on: 
Thursday, February 4, 2021
Vision, Branches of biology, Ion channels, Nervous system, Channelopathies, Cyclic nucleotide gated channel beta 3, Achromatopsia, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa, Retinitis, Applied Genetic Technologies Corporation

The AGTC authors article received the highest number of votes from BPI readers, who ranked the nominees in terms of their innovativeness, presentability and applicability.

Key Points: 
  • The AGTC authors article received the highest number of votes from BPI readers, who ranked the nominees in terms of their innovativeness, presentability and applicability.
  • AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia

Retrieved on: 
Tuesday, January 26, 2021
Vision, Nervous system, Sensory systems, Achromatopsia, Agnosía, Channelopathies, Visual perception, Visual system, Cyclic nucleotide-gated channel alpha 3, Orphan drug, Fast track, European Medicines Agency

MeiraGTx is currently conducting an open-label, dose-escalation Phase 1/2 clinical trial of AAV-CNGA3 in patients with ACHM due to mutations in the CNGA3 gene.

Key Points: 
  • MeiraGTx is currently conducting an open-label, dose-escalation Phase 1/2 clinical trial of AAV-CNGA3 in patients with ACHM due to mutations in the CNGA3 gene.
  • Fast Track designation enables the company to have early and frequent communication with the FDA throughout the drug development and review process, with the potential for faster drug approval and patient access.
  • AAV-CNGA3 has already been granted Orphan Drug designation by the FDA and European Medicines Agency (EMA).
  • This is the third Fast Track designation MeiraGTx has received for its inherited retinal disease product candidates, having previously received Fast Track designation for AAV-RPGR and AAV-CNGB3, as well as having received PRIME designation for AAV-RPGR and AAV-CNGB3 from the EMA.

AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference

Retrieved on: 
Wednesday, January 6, 2021
Vision, Branches of biology, Nervous system, Ion channels, Channelopathies, Achromatopsia, Agnosía, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa

The fireside chat will be available to view on-demand beginning Monday, January 11, 2021 at 6:00AM ET through the entirety of the conference and available by visiting http://ir.agtc.com/events-and-presentations .

Key Points: 
  • The fireside chat will be available to view on-demand beginning Monday, January 11, 2021 at 6:00AM ET through the entirety of the conference and available by visiting http://ir.agtc.com/events-and-presentations .
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

Retrieved on: 
Wednesday, November 11, 2020
Branches of biology, Biology, Vision, Ion channels, Channelopathies, Achromatopsia, Agnosía, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis

The Company plans to initiate its Skyline trial by enrolling approximately 12 additional patients total in Group 2 (1.2E+11 vg/mL) and Group 5 (1.1E+12 vg/mL).

Key Points: 
  • The Company plans to initiate its Skyline trial by enrolling approximately 12 additional patients total in Group 2 (1.2E+11 vg/mL) and Group 5 (1.1E+12 vg/mL).
  • With further investigation, there is a high likelihood that this gene therapy candidate could become a meaningful treatment for patients with XLRP.
  • Data from all 28 patients across six dose groups continue to demonstrate a favorable safety profile with no dose-limiting inflammatory responses observed.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3).

AGTC to Present at Upcoming Virtual Conferences

Retrieved on: 
Thursday, October 8, 2020
Vision, Perception, Ion channels, Senses, Channelopathies, Achromatopsia, Agnosía, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.

Key Points: 
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance on Patient Perspectives for Pipeline Therapies

Retrieved on: 
Wednesday, August 12, 2020
Vision, Perception, Senses, Channelopathies, Ion channels, Achromatopsia, Agnosía, Visual perception, Visual system, Applied Genetic Technologies Corporation, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3

AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.

Key Points: 
  • AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.
  • The Companys most advanced clinical programs leverage its best-in-class investigational technology platform to potentially improve vision for patients with an inherited retinal disease.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC to Present at the Wedbush PacGrow Virtual Healthcare Conference on August 11, 2020

Retrieved on: 
Tuesday, August 4, 2020
Vision, Perception, Senses, Channelopathies, Ion channels, Achromatopsia, Agnosía, Visual perception, Visual system, Applied Genetic Technologies Corporation, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3

A live audio webcast of the presentation will be available by visiting http://ir.agtc.com/events-and-presentations .

Key Points: 
  • A live audio webcast of the presentation will be available by visiting http://ir.agtc.com/events-and-presentations .
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial

Retrieved on: 
Wednesday, July 22, 2020
Vision, Perception, Health, Channelopathies, Ion channels, Achromatopsia, Agnosía, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Applied Genetic Technologies Corporation

The revised development plan, which includes immediate expansion of the current trial in parallel with the planned Phase 2/3 trial, will be designed to evaluate sustained efficacy across multiple measures of potential benefit in patients with XLRP.

Key Points: 
  • The revised development plan, which includes immediate expansion of the current trial in parallel with the planned Phase 2/3 trial, will be designed to evaluate sustained efficacy across multiple measures of potential benefit in patients with XLRP.
  • The Company continues to move forward as planned with manufacturing, clinical site preparation and other activities to enable initiation of the studies as quickly as possible.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020

Retrieved on: 
Tuesday, June 16, 2020
Vision, Perception, Channelopathies, Senses, Ion channels, Achromatopsia, Agnosía, Visual perception, Visual system, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa, Cyclic nucleotide gated channel beta 3

A replay will be available on the company's website following the event.

Key Points: 
  • A replay will be available on the company's website following the event.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.